Clinical Management

Remission for cardiac light chain amyloidosis for >1 year may be associated with changes in myocardial composition without a reduction in extracellular volume. Read More ›

A new study reports high antibody response rates after COVID-19 vaccination among patients with monoclonal gammopathies of unknown significance, smoldering myeloma, multiple myeloma, or light chain amyloidosis. Read More ›

As with the ventricles, amyloid infiltration in the atria may affect the severity of transthyretin amyloid cardiomyopathy. Read More ›

A study examined the hematologic and organ response rates to daratumumab in patients with relapsed/refractory light chain amyloidosis. Read More ›

Ixazomib plus dexamethasone may not improve response rate compared with physician’s choice of care but may delay organ deterioration and mortality in relapsed/refractory light chain amyloidosis. Read More ›

Results of a recent study suggest that patients with cardiac amyloidosis are less likely to respond to cardiac resynchronization therapy than patients with dilated cardiomyopathy. Read More ›

AG10 has the potential to be clinically efficacious in patients with a variety of genotypes associated with both TTR cardiomyopathy and polyneuropathy. Read More ›


The ANDROMEDA study revealed a significant hematologic complete response rate in patients with newly diagnosed light chain amyloidosis treated with daratumumab plus hyaluronidase human-fihj. Read More ›

The presence of severe aortic stenosis in the context of transthyretin cardiac amyloidosis is associated with a dramatic reduction in patient survival. Read More ›

Page 1 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: